Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human / Cynomolgus / Rhesus macaque CD28, Fc Tag, Avi Tag (Avitag™) active dimer (MALS verified), 200µg  

Recombinant Biotinylated Human / Cynomolgus / Rhesus macaque CD28, Fc Tag, Avi Tag (Avitag™) active dimer (MALS verified), 200µg

Biotinylated Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (CD8-H82F2), Avitag™, expressed from human 293 cells (HEK293), active dimer (MALS verified)

Synonym
recombinant, human, biotinylated, protein, CD28,Tp44

More details

CD8-H82F2-200

Availability: within 7 days

1 078,00 €

Background
T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. It is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.

Source
Recombinant Biotinylated Human / Cynomolgus / Rhesus macaque CD28, Fc,Avitag (CD8-H82F2) is expressed from human 293 cells (HEK293). It contains AA Asn 19 - Pro 152 (Accession # AAH93698). In the region Asn 19 - Pro 152, the AA sequence of Human, Cynomolgus and Rhesus macaque CD28 are homologus.
Predicted N-terminus: Asn 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 43.6 kDa. As a result of glycosylation, the protein migrates as 55-70 kDa under reducing (R) condition, and 110-130 kDa under non-reducing (NR) condition (SDS-PAGE).

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) " 'Off-the-Shelf' Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells"
Boyd, Cartledge, Cao et al
Cells (2021) 10 (10)
(2) "Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients"
Coleman, Zimmerly, Yang
Biomolecules (2021) 11 (10)
(3) "CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients"
Gimeno, González-Lozano, Soto-Ramírez et al
Oncoimmunology (2021) 10 (1), 1986943
Showing 1-3 of 12223 papers.

 

 

 

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.